CORAL GABLES, FL / ACCESSWIRE / April 4, 2019 / The success of the healthcare stock market is directly connected to the fact that companies in the healthcare industry are committed to improving the quality of life for consumers in need. According to the most recent global report from the United Nations, by the year 2030, the global population will reach 8.6 billion. This predicted growth is an indicator that more people will soon need access to quality medical care and the healthcare sector must be aptly prepared. Luckily, over the last few months, we've seen companies take initiative to develop innovative new medical technologies and optimize their care offerings to meet the growing needs of the global community. As the healthcare sector continues to progress into the future, investors interested in potentially lucrative opportunities could benefit from focusing on this sector. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Shineco Inc (TYHT), Tonix Pharmaceuticals Holding Corp (TNXP), and Sunesis Pharmaceuticals Inc (SNSS) are 4 healthcare companies worth keeping on your radar.
Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company determined to develop innovative approaches that combine human skill-based expertise with state-of-the-art technologies to offer to their patients the best possible treatment solutions and primary care. At a time where consumers depend on healthcare companies to provide quality care solutions, Premier Health is prepared to meet the needs of its patients.
Premier Health Group (OTC:PHGRF) (CSE:PHGI) earlier this week announced a non-brokered placement of up to 4,615,384 units at a price of $0.65 per unit for gross proceeds of up to $3,000,000. Each unit will consist of one common share and one-half of a share purchase warrant. Each whole warrant will be exercisable for an additional share at a price of $1.00 for a period of two years from issuance. Per the details of the announcement, the Company will use the net proceeds to fund its ongoing growth strategy in the technology healthcare space and for working capital purposes.
The Company also announced that certain lead investors to its previous placement completed in July 2018, representing approximately five million shares, have agreed to voluntarily restrict their shares from trading until August 2019.
Shineco Inc (TYHT), a producer and distributor of Chinese herbal medicines, organic produce, and various health-focused products in China, today announced that the Company through its wholly owned subsidiary Tenjove NewHemp Biotech Co., Ltd., entered into a strategic cooperation agreement with the Xingshan People's Government of Hegang City of Heilongjiang Province. Per the details of the agreement, both parties agree to actively promote the development of a complete industrial chain for industrial hemp including cultivation, harvesting, initial processing, and fine extraction to form a local industry integration model and to achieve a new industrial-scale economy.
Mr. Yuying Zhang, Chairman, and CEO of Shineco said, "we are pleased to announce this agreement with the Xingshan People's Government of Hegang City. We expect an annual production of 30 tons of CBD extract, and other raw medical materials from our industrial hemp project, along with 2,000 tons of industrial hemp fiber, 500 tons of industrial hemp seed oil and 4,000 tons of hemp leaves. We estimate the value of the CBD and related raw medical extract alone to reach RMB2.1 billion, given the robust demand for CBD products and the resulting high market price."
Tonix Pharmaceuticals Holding Corp (TNXP) saw its shares enjoy a 22.75% boost to Thursday's trading, with its shares trading at $2.87 per share in the mid-afternoon. The biopharmaceutical company today announced the expansion of the TNX-102 SL 5.6 mg program beyond posttraumatic stress disorder to include Phase 3 development for TNX-102 SL* in fibromyalgia.
Following the expansion update, Seth Lederman, President, and CEO of Tonix said, "we are very pleased with the outcomes of our recent discussion with the FDA to advance the fibromyalgia Phase 3 clinical program with TNX-102 SL 5.6 mg with the potential to expand the product labeling beyond PTSD. The FDA's acceptance of the well-established safety information of currently-marketed oral cyclobenzaprine products and their agreement that TNX-102 SL 5.6 mg long-term exposure data from our PTSD studies may support the fibromyalgia indication are very reassuring."
Sunesis Pharmaceuticals Inc (SNSS), a biopharmaceutical company working to develop novel therapeutics for the treatment of hematologic and solid cancers, yesterday announced that Willie Quinn, the Company's Chief Financial Officer, and Senior Vice President, will present at the upcoming Needham & Company 18th Annual Healthcare Conference on Wednesday, April 10, 2019 at 2:10 PM Eastern Time at the Westin Grand Central Hotel in New York City.
Per the details of the announcement, the Company's presentation will be live-streamed during the event, and a replay will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid "500,000" shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to June 1, 2019. As of 3/26/2019 Midam has been compensated an additional $100,000 by Premier Health Group for additional coverage without further extended coverage duration. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
View source version on accesswire.com: